ELI LILLY & Co (LLY) operating KPIs
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1417.54+43.84 (+3.19%)
Close on Oct 30, 2026Market cap $1.33TP/E 46.0Yield 0.44%
Eli Lilly zyprexa (olanzapine) — Worldwide revenue YoY (%) [legacy] (%)
Quarterly figures from Eli Lilly's filings and investor materials
Latest, Q3 2024
-98.0%
Period ended Sep 30, 2024
Change on a year earlier
-171.4 pts
73.4% in Q3 2023
History
17 quarters
Since Q1 2018
Sources
17
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Eli Lilly Zyprexa (olanzapine) — Worldwide revenue YoY (%) [legacy] (%), quarterly Q1 2018–Q3 2024 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med_zyprexa_yoy
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.